Study of Orally Disintegrating Tablets Using Erythritol as an Excipient Produced by Moisture-Activated Dry Granulation (MADG).

disintegration erythritol moisture-activated dry granulation orally disintegrating tablet water activity

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
15 Aug 2022
Historique:
received: 28 07 2022
revised: 09 08 2022
accepted: 11 08 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 27 8 2022
Statut: epublish

Résumé

Moisture-activated dry granulation (MADG) is an eco-friendly granulation method that uses a small amount of water and insoluble excipients to absorb moisture. MADG is expected to improve productivity and reduce costs. Erythritol, an excipient used for preparing orally disintegrating tablets (ODTs), has poor tabletability and is difficult to form into tablets by conventional methods, such as high-shear granulation (HSG) and direct compression. In this study, we optimized the manufacturing conditions for ODTs to improve the tabletability of erythritol using MADG. The disintegration time of tablets made using the MADG method was approximately one-tenth that of those made using the HSG method, and the hardness was approximately 1.4 times higher. Moreover, MADG could delay disintegration and improve tabletability. We further attempted to optimize the manufacturing conditions using MADG, particularly in terms of the amount of water used. The disintegration time increased as the amount of added water increased. Moreover, water absorption tests revealed that capillary wetting decreased as the amount of water added increased, but the initial wetting did not change. These results suggested that the disintegration time was prolonged because of the increase in granule density and decrease in capillary wetting with the increase in the amount of added water. The hardness of the tablets increased because of the easy deformation of the granules after the addition of up to 3% water; however, when more than 3% water was added, the hardness decreased because of the aggregation of the granules with the excess water. Finally, two-dimensional maps of the effect of the amount of added water and water activity indicated that tablets with a hardness of ≥80 N and a disintegration time of ≤15 s could be produced by adjusting the amount of added water to within the range of 2.2-3.3% and water activity to 0.3-0.53. These results indicate that MADG can improve the tabletability of erythritol and be used for the granulation of ODTs. Tablets with appropriate hardness and disintegration properties can be produced by adjusting the water content to approximately 2.7% and the water activity to approximately 0.4 when producing ODTs with MADG.

Identifiants

pubmed: 36015152
pii: ph15081004
doi: 10.3390/ph15081004
pmc: PMC9415806
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Gastroenterology. 1999 Feb;116(2):455-78
pubmed: 9922328
Drug Dev Ind Pharm. 1999 May;25(5):571-81
pubmed: 10219525
Int J Pharm. 2005 Dec 8;306(1-2):83-90
pubmed: 16257154
Drug Dev Ind Pharm. 2013 Nov;39(11):1802-8
pubmed: 23163644
Drug Dev Ind Pharm. 2000 Aug;26(8):885-9
pubmed: 10900546
Int J Pharm. 2012 Dec 15;439(1-2):324-33
pubmed: 22981985
Int J Pharm. 2011 Jun 15;411(1-2):152-61
pubmed: 21497644
Pharmaceutics. 2020 Jun 27;12(7):
pubmed: 32605039
J Pharm Sci. 2010 Aug;99(8):3322-5
pubmed: 20232456
Int J Pharm. 2013 Nov 1;456(1):58-64
pubmed: 23994013
Int J Pharm. 2009 Dec 1;382(1-2):80-7
pubmed: 19686825
Crit Rev Ther Drug Carrier Syst. 2000;17(1):61-72
pubmed: 10755211
Pharm Dev Technol. 2013 Feb;18(1):210-24
pubmed: 22780851
Int J Pharm. 2008 May 1;355(1-2):87-92
pubmed: 18182258
Int J Pharm. 2019 Feb 25;557:18-25
pubmed: 30572077
Pharm Sci Technol Today. 2000 Feb;3(2):58-63
pubmed: 10664574
Pharmaceutics. 2022 Apr 16;14(4):
pubmed: 35456710
Curr Pharm Des. 2015;21(40):5877-89
pubmed: 26446468
Pharmaceutics. 2021 Dec 15;13(12):
pubmed: 34959447
Int J Pharm. 2018 May 30;543(1-2):288-299
pubmed: 29625168
AAPS PharmSciTech. 2003 Dec 15;4(4):E62
pubmed: 15198557
Int J Pharm. 2006 Mar 9;310(1-2):101-9
pubmed: 16434157
Int J Pharm. 2000 Mar 30;198(1):51-61
pubmed: 10722950
Dysphagia. 1991;6(4):187-92
pubmed: 1778094
Pharm Dev Technol. 2001 Nov;6(4):487-93
pubmed: 11775950
Drug Dev Ind Pharm. 2001 Oct;27(9):893-8
pubmed: 11763466
Eur J Clin Pharmacol. 2013 Apr;69(4):937-48
pubmed: 23052416
Pharm Res. 2006 Mar;23(3):634-40
pubmed: 16382277
Int J Pharm. 2016 Aug 20;510(1):195-202
pubmed: 27184101
J Pharm Sci. 2019 Oct;108(10):3209-3217
pubmed: 31233756
Semin Speech Lang. 2000;21(4):347-61
pubmed: 11085258
J Pharm Sci. 1970 May;59(5):688-91
pubmed: 5446428
Int J Pharm Investig. 2015 Oct-Dec;5(4):266-74
pubmed: 26682197
Yakugaku Zasshi. 1998 Apr;118(4):127-42
pubmed: 9564790

Auteurs

Mizuki Yamada (M)

Department of Physical Chemistry, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-ku 142-8501, Tokyo, Japan.

Agata Ishikawa (A)

Department of Physical Chemistry, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-ku 142-8501, Tokyo, Japan.

Shun Muramatsu (S)

Department of Physical Chemistry, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-ku 142-8501, Tokyo, Japan.

Takayuki Furuishi (T)

Department of Physical Chemistry, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-ku 142-8501, Tokyo, Japan.

Yoshinori Onuki (Y)

Laboratory of Pharmaceutical Technology, School of Pharmacy and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama-shi 930-0194, Toyama, Japan.

Kaori Fukuzawa (K)

Department of Physical Chemistry, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-ku 142-8501, Tokyo, Japan.
Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita 565-0871, Osaka, Japan.

Etsuo Yonemochi (E)

Department of Physical Chemistry, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-ku 142-8501, Tokyo, Japan.

Classifications MeSH